STOCK TITAN

Fortress Biotech CFO buys 47.6K common shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Fortress Biotech, Inc. (FBIO) Chief Financial Officer David Jin made three direct common-stock purchases totaling 47,605 shares from November 17 through November 19, 2026. The weighted-average prices were $1.7197 for 15,000 shares on November 17 (range $1.71–$1.72), $1.9119 for 25,000 shares on November 18 (range $1.8999–$1.96), and $1.8699 for 7,605 shares on November 19 (range $1.865–$1.87). The purchases were not reported as made under a Rule 10b5-1 plan.

Insider Jin David
Role Chief Financial Officer
Bought 47,605 shs ($88K)
Type Security Shares Price Value
Purchase Common Stock, par value $0.001 F1, F2 7,605 $1.8699 $14K
Purchase Common Stock, par value $0.001 F1, F2 25,000 $1.9119 $48K
Purchase Common Stock, par value $0.001 F1, F2 15,000 $1.7197 $26K
Holdings After Transaction: Common Stock, par value $0.001 — 1,700,366 shares (Direct)
Footnotes (2)
  1. F1. The prices reported in Column 4 are weighted average prices. The shares were purchased in multiple transactions in prices ranging from $1.71 to $1.72 on November 17, 2026, $1.8999 to $1.96 on November 18, 2026, and $1.865 to $1.87 on November 19, 2026, in each case inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this note.
  2. F2. Total holdings include 1,230,000 shares underlying deferred restricted stock units and 400,000 shares underlying restricted stock units.
Shares purchased 47,605 shares Across three direct purchases from November 17 through November 19, 2026
Shares purchased 15,000 shares November 17, 2026
Weighted-average purchase price $1.7197 per share November 17, 2026
Shares purchased 25,000 shares November 18, 2026
Weighted-average purchase price $1.9119 per share November 18, 2026
Shares purchased 7,605 shares November 19, 2026
Weighted-average purchase price $1.8699 per share November 19, 2026
weighted average prices financial
"The prices reported in Column 4 are weighted average prices"
deferred restricted stock units financial
"1,230,000 shares underlying deferred restricted stock units"
Deferred restricted stock units are promises by a company to give employees or executives company shares at a future date, subject to conditions like continued employment or performance targets; the delivery and tax event are intentionally delayed. They matter to investors because they affect when new shares may be issued and how executives are motivated—like a paycheck held in escrow that vests over time, influencing potential share dilution and management behavior.
restricted stock units financial
"400,000 shares underlying restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Fortress Biotech (FBIO) CFO David Jin buy, and at what prices?

David Jin, Fortress Biotech's chief financial officer, bought 47,605 shares in three direct purchases on November 17, 18 and 19, 2026. The weighted-average prices were $1.7197, $1.9119 and $1.8699 per share, respectively; the price ranges for those dates were $1.71–$1.72, $1.8999–$1.96 and $1.865–$1.87. The purchases were not reported as made under a Rule 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Jin David

(Last)(First)(Middle)
C/O FORTRESS BIOTECH, INC.
1111 KANE CONCOURSE SUITE 301

(Street)
BAY HARBOR ISLANDS FLORIDA 33154

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Fortress Biotech, Inc. [ FBIO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, par value $0.00111/17/2026P15,000A$1.7197(1)1,667,761(2)D
Common Stock, par value $0.00111/18/2026P25,000A$1.9119(1)1,692,761(2)D
Common Stock, par value $0.00111/19/2026P7,605A$1.8699(1)1,700,366(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The prices reported in Column 4 are weighted average prices. The shares were purchased in multiple transactions in prices ranging from $1.71 to $1.72 on November 17, 2026, $1.8999 to $1.96 on November 18, 2026, and $1.865 to $1.87 on November 19, 2026, in each case inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this note.
2. Total holdings include 1,230,000 shares underlying deferred restricted stock units and 400,000 shares underlying restricted stock units.
/s/ David Jin11/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading